View More Recent Stories

Dec 11, 2024 04:39AM Increasing unusual call option volume: RGTI QURE GSAT CRDF PL QUBT ALK KULR BRZE QBTS UNFI UAA XP SFIX MTN
Dec 10, 2024 11:28AM Raymond James Upgrades uniQure BV (QURE) to Strong Buy
Dec 10, 2024 10:22AM Increasing unusual call option volume: QURE RGTI PL KULR BRZE UNFI VSTS MTN ASAN QUBT
Dec 10, 2024 08:04AM Stifel on uniQure (QURE): 'we believe this is a big win for the stock'
Dec 10, 2024 07:08AM uniQure (QURE) Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
Nov 5, 2024 07:34AM uniQure (QURE) Tops Q3 EPS by 11c
Oct 15, 2024 07:05AM uniQure (QURE) Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
Oct 10, 2024 08:24AM Raymond James Resumes uniQure BV (QURE) at Outperform
Sep 23, 2024 07:09AM uniQure (QURE) Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
Aug 20, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
Jul 11, 2024 05:56AM Increasing unusual option volume: EWC QURE SGH HA LZ UROY RGTI
Jul 10, 2024 03:03PM uniQure (QURE) call put ratio 3 calls to 1 put amid share price up 65%
Jul 10, 2024 08:29AM H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
Jul 9, 2024 12:30PM TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
Jul 9, 2024 07:05AM uniQure (QURE) Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
Jul 1, 2024 07:05AM uniQure (QURE) to Sell Gene Therapy Manufacturing Operations in Lexington, MA to Genezen
View More Recent Stories